Kathleen Madden on Managing AEs From Targeted Therapies for Melanoma

Article

Kathleen M. Madden discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.

Kathleen M. Madden, MSN, FNP-BC, AOCNP®, APHN, from Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the management of adverse events (AEs) with BRAF and MEK inhibitors for the treatment of patients with melanoma.

The entire process starts with trust and a good relationship between the patient and nurse, Madden says. Patients need to be taught that no matter how minor an issue may seem on the surface, it could develop into something more significant. On a similar note, patients don’t always understand the significance of a side effect before treatment begins.

Madden says in her workflow, she and other nurses appreciate when patients call if they have a question, but they don’t always call early enough.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Image of a woman with white hair in front of an Oncology Nursing News blue background
2 experts are featured in this series.
Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
Related Content